## The Prevalence and 5-Year Incidence Rate of Cigarette Smoking and Water-Pipe Tobacco Smoking and Their Associated Factors among 15 to 80 Years Old Urban Population in Southeast Iran: Results from KERCADR Study

Hamid Najafipour<sup>1</sup>, Amin Mahdavi<sup>2\*</sup>, Zeinab Kordestani<sup>3</sup>, Zahra Zamaninasab<sup>4</sup>, Mitra Shadkam Farokhi<sup>5</sup>, Atefeh Shamsadini<sup>6</sup>, Elnaz Azizi<sup>6</sup>

<sup>&</sup>lt;sup>1</sup>Physiology Research Center, Institute of Neuropharmacology, and Department of Physiology and Pharmacology, Kerman University of Medical Sciences, Kerman, Iran

<sup>&</sup>lt;sup>2</sup>Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences and Department of Cardiology, Kerman University of Medical Sciences, Kerman, Iran

<sup>&</sup>lt;sup>3</sup>Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

<sup>&</sup>lt;sup>4</sup>Department of Biostatistics, Faculty of Health, and Gastroenterology and Hepatology Research Center, Kerman University of Medical Sciences, Kerman, Iran

<sup>&</sup>lt;sup>5</sup>Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran

<sup>&</sup>lt;sup>6</sup>Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

## Supplementary file 1




Figure 1 supplement- Flow chart of people participated in both phases of the study

**Table S1.** The prevalence of cigarette smoking, n (%) in phases 1 and 2 of the KERCADR study, Kerman, Iran (n=5716 in phase 1, 2009-2012 and n=10015 in phase 2, 2014-2018). The data of phase 1 were extracted from the previous publication and presented here for comparison (15).

Subgroup	Phase 1	Phase 2	P-value
Overall	8.1(7-9)	8.8(8.2-9.4)	.178
Male	15.0(14-17)	17(16-18)	.269
Female	0.8 (0.5-1)	0.5(0.4-0.7)	.062
15-24 years	1.7(0. 9-3.2)	2.9(1.8-4.6)	.183
Male	3.4(2-6)	5(3-8)	.174
Female	0	0	
25-34 years	8.3(7-10)	5.8(4.6-7.2)	.005
Male	16(13-19)	11(9-13)	.026
Female	0.6(0.2-1.8)	0.4(0.1-1.1)	.544
35-44 years	13(11-15)	11(9.7-12.7)	.027
Male	25(21-29)	22(19-25)	.297
Female	0.8(0.3-1.9)	0.1(0-0.6)	.083
45-54 years	18(16-20)	15(13.5-16.8)	.006
Male	33(29-37)	30(27-33)	.204
Female	2.2(1.4-3.6)	0.4(.2-1)	.003
55-64 years	13(11-15)	15.7(14.7-17.3)	.823
Male	24(21-28)	30(27-33)	.026
Female	1.7(0.8-3.2)	0	.887
65-74 years	9(7-12)	10.2(8.6-12.1)	.694
Male	16(12-21)	19(16-22)	.273
Female	1.5(0.6-4)	1.4(0.7-2.7)	.925
>75 years		7.8(5.8-10.4)	
Male		14	
Female		1.5	